Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1)
- PMID: 10545614
- DOI: 10.1093/hmg/8.12.2325
Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1)
Abstract
Cerebral cavernous malformations (CCM) are congenital vascular anomalies of the brain that can cause significant neurological disabilities, including intractable seizures and hemorrhagic stroke. One locus for autosomal dominant CCM ( CCM1 ) maps to chromosome 7q21-q22. Recombination events in linked family members define a critical region of approximately 2 Mb and a shared disease haplotype associated with a presumed founder effect in families of Mexican-American descent points to a potentially smaller region of interest. Using a genomic sequence-based positional cloning strategy, we have identified KRIT1, encoding a protein that interacts with the Krev-1/rap1a tumor suppressor, as the CCM1 gene. Seven different KRIT1 mutations have been identified in 23 distinct CCM1 families. The identical mutation is present in 16 of 21 Mexican-American families analyzed, substantiating a founder effect in this population. Other Mexican-American and non-Hispanic Caucasian CCM1 kindreds harbor other KRIT1 mutations. Identification of a common Mexican-American mutation has potential clinical significance for presymptomatic diagnosis of CCM in this population. In addition, these data point to a key role for the Krev-1/rap1a signaling pathway in angiogenesis and cerebrovascular disease.
Similar articles
-
Mutational analysis of 206 families with cavernous malformations.J Neurosurg. 2003 Jul;99(1):38-43. doi: 10.3171/jns.2003.99.1.0038. J Neurosurg. 2003. PMID: 12854741
-
Mutations in KRIT1 in familial cerebral cavernous malformations.Neurosurgery. 2000 May;46(5):1272-7; discussion 1277-9. doi: 10.1097/00006123-200005000-00064. Neurosurgery. 2000. PMID: 10807272
-
Identification of Krit1B: a novel alternative splicing isoform of cerebral cavernous malformation gene-1.Gene. 2004 Jan 21;325:63-78. doi: 10.1016/j.gene.2003.09.046. Gene. 2004. PMID: 14697511
-
Cerebral cavernous malformations: mutations in Krit1.Neurology. 2002 Mar 26;58(6):853-7. doi: 10.1212/wnl.58.6.853. Neurology. 2002. PMID: 11914398 Review.
-
Familial cerebral cavernous malformations: Rio de Janeiro study and review of the recommendations for management.Arq Neuropsiquiatr. 2008 Dec;66(4):795-9. doi: 10.1590/s0004-282x2008000600003. Arq Neuropsiquiatr. 2008. PMID: 19099113 Review.
Cited by
-
CCM molecular screening in a diagnosis context: novel unclassified variants leading to abnormal splicing and importance of large deletions.Neurogenetics. 2013 May;14(2):133-41. doi: 10.1007/s10048-013-0362-0. Epub 2013 Apr 18. Neurogenetics. 2013. PMID: 23595507
-
Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development.Sci Signal. 2010 Apr 6;3(116):ra26. doi: 10.1126/scisignal.2000722. Sci Signal. 2010. PMID: 20371769 Free PMC article.
-
A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.Transl Stroke Res. 2020 Jun;11(3):365-376. doi: 10.1007/s12975-019-00725-8. Epub 2019 Aug 24. Transl Stroke Res. 2020. PMID: 31446620 Free PMC article.
-
Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.J Exp Med. 2010 Apr 12;207(4):881-96. doi: 10.1084/jem.20091258. Epub 2010 Mar 22. J Exp Med. 2010. PMID: 20308363 Free PMC article.
-
Next-Generation Sequencing Advances the Genetic Diagnosis of Cerebral Cavernous Malformation (CCM).Antioxidants (Basel). 2022 Jun 29;11(7):1294. doi: 10.3390/antiox11071294. Antioxidants (Basel). 2022. PMID: 35883785 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous